Chelation therapy for iron overload.
Chelation therapy for iron overload.
复制标题
DOI：
10.1007/s11894-008-0024-9
复制
发表时间：
2007-03-01
影响因子：
--
通讯作者：
Barton, James C
中科院分区：
文献类型：
--
作者：
Barton, James C
铁超负荷的特征是铁沉积过多，从而导致心脏、肝脏、垂体前叶、胰腺和关节的损伤和功能障碍。由于排泄铁的生理机制非常有限，铁超负荷及其并发症的患者需要与其共存医疗状况相适应的安全、有效的治疗。三种获得许可的铁螯合药物（一种肠胃外，两种口服）的可用性以及其他口服螯合剂的开发和临床研究为预防或管理遗传性严重贫血（如重型β地中海贫血和镰状细胞病）患者的铁超载提供了新的机会，并为与 HFE 基因相关的铁超载和其他成人发病年龄类型的血色素沉着症、非洲铁超载和非洲裔美国人制定静脉切开术治疗的替代方案。铁过载。
Iron overload is characterized by excessive iron deposition and consequent injury and dysfunction of the heart, liver, anterior pituitary, pancreas, and joints. Because physiologic mechanisms to excrete iron are very limited, patients with iron overload and its complications need safe, effective therapy that is compatible with their coexisting medical conditions. The availability of three licensed iron chelation drugs (one parenteral, two oral) and the development and clinical investigation of other oral chelators represent new opportunities to prevent or manage iron overload in patients with heritable types of severe anemia, such as beta-thalassemia major and sickle cell disease, and for the formulation of alternatives to phlebotomy therapy for patients with iron overload associated with the HFE gene and other adult age-of-onset types of hemochromatosis, African iron overload, and African-American iron overload.